文献速递肺血管病与心包/心肌炎血脂与心血管预防

他汀剂量与外周动脉疾病截肢及生存的关联

Association of Statin Dose With Amputation and Survival in Patients With Peripheral Artery Disease.
PubMed 文献 · Circulation · 2018-01-12

结果显示,与仅用抗血小板治疗者相比,高强度他汀与较低的截肢风险(HR 0.67,95%CI 0.61-0.74)和死亡风险(HR 0.74,95%CI 0.70-0.77)相关,低至中等强度他汀亦显示获益但效应较弱。

要点

  • PAD患者他汀使用不足,仅6.4%单纯PAD患者使用高强度他汀。
  • 高强度他汀与较低的截肢和死亡风险相关,优于低至中等强度他汀。
  • 与仅用抗血小板治疗相比,任何他汀使用均与截肢和死亡风险降低相关。

核心结论

  • PAD患者他汀尤其高强度他汀使用不足;确诊时使用高强度他汀与较低的截肢和死亡风险相关。

研究设计与样本

  • 根据PAD诊断后1年内最高他汀强度暴露分为高强度、低至中等强度及仅抗血小板无他汀三组。
  • 采用Kaplan-Meier曲线、Cox比例风险模型、倾向评分匹配分析及敏感性和亚组分析评估关联。

主要发现

  • 单纯PAD患者高强度他汀使用率6.4%,合并冠脉/颈动脉疾病者为18.4%。
  • 校正Cox模型显示,高强度他汀组较仅抗血小板组截肢风险HR 0.67(95%CI 0.61-0.74),死亡风险HR 0.74(95%CI 0.70-0.77)。
  • 低至中等强度他汀组较仅抗血小板组截肢风险HR 0.81(95%CI 0.75-0.86),死亡风险HR 0.83(95%CI 0.81-0.86),效应弱于高强度他汀(P<0.001)。
  • 高强度他汀与较低截肢和死亡风险的关联在倾向评分匹配、敏感性和亚组分析中保持显著稳健。

临床怎么用

  • 对PAD患者应评估他汀使用情况,尤其关注高强度他汀的未充分利用。
  • 确诊PAD时可考虑使用高强度他汀以降低截肢和死亡风险。
  • 不应仅用抗血小板治疗而忽略他汀治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Statin dose guidelines for patients with peripheral artery disease (PAD) are largely based on coronary artery disease and stroke data. The aim of this study is to determine the effect of statin intensity on PAD outcomes of amputation and mortality. METHODS: Using an observational cohort study design and a validated algorithm, we identified patients with incident PAD (2003-2014) in the national Veterans Affairs data. Highest statin intensity exposure (high-intensity versus low-to-moderate-intensity versus antiplatelet therapy but no statin use) was determined within 1 year of diagnosis of PAD. Outcomes of interest were lower extremity amputations and death. The association of statin intensity with incident amputation and mortality was assessed with Kaplan-Meier plots, Cox proportional hazards modeling, propensity score-matched analysis, and sensitivity and subgroup analyses, as well, to reduce confounding. RESULTS: In 155 647 patients with incident PAD, more than a quarter (28%) were not on statins. Use of high-intensity statins was lowest in patients with PAD only (6.4%) in comparison with comorbid coronary/carotid disease (18.4%). Incident amputation and mortality risk declined significantly with any statin use in comparison with the antiplatelet therapy-only group. In adjusted Cox models, the high-intensity statin users were associated with lower amputation risk and mortality in comparison with antiplatelet therapy-only users (hazard ratio, 0.67; 95% confidence interval, 0.61-0.74 and hazard ratio, 0.74; 95% confidence interval, 0.70-0.77, respectively). Low-to-moderate-intensity statins also had significant reductions in the risk of amputation and mortality (hazard ratio amputation, 0.81; 95% confidence interval, 0.75- 0.86; hazard ratio death, 0.83; 95% confidence interval, 0.81-0.86) in comparison with no statins (antiplatelet therapy only), but effect size was significantly weaker than the high-intensity statins (P<0.001). The association of high-intensity statins with lower amputation and death risk remained significant and robust in propensity score-matched, sensitivity, and subgroup analyses. CONCLUSIONS: Statins, especially high-intensity formulations, are underused in patients with PAD. This is the first population-based study to show that high-intensity statin use at the time of PAD diagnosis is associated with a significant reduction in limb loss and mortality in comparison with low-to-moderate-intensity statin users, and patients treated only with antiplatelet medications but not with statins, as well.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Arya S, Khakharia A, Binney ZO, et al. Association of Statin Dose With Amputation and Survival in Patients With Peripheral Artery Disease. Circulation. 2018. PMID: 29330214. doi:10.1161/CIRCULATIONAHA.117.032361

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。